Doxorubicin Market To Reach $1.53 Billion By 2030 | CAGR 6.6%

Doxorubicin Market Growth & Trends

The global doxorubicin market size is expected to reach USD 1.53 billion by 2030, registering a CAGR of 6.6% during the forecast period, according to a new report by Grand View Research, Inc. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.

The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: -

• Leukemia                    60,140

• Breast cancer             2,46,660

• Endometrial cancer    60,050

• Gastric cancer           26,370

• Liver cancer                39,230

• Kidney Cancer            62,700

According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.

 Request a free sample copy or view report summary: Doxorubicin Market Report

Doxorubicin Market Report Highlights

• In 2023, breast cancer is the largest application of doxorubicin market. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.

• Bladder cancer segment projected to grow at a significant CAGR during the forecast period. Doxorubicin, which has been a standard treatment for advanced bladder cancer, remains a critical component in the management of the disease.

• In 2023, North America held majority of market share of over 37.7% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.

• Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.

Doxorubicin Market Segmentation

Grand View Research has segmented the global doxorubicin market based on drug formulation, application, distribution channel, and region:

Doxorubicin Formulation Outlook (Revenue, USD Million, 2018 - 2030)

• Lyophilized Powder

• Doxorubicin Injection

Doxorubicin Application Outlook (Revenue, USD Million, 2018 - 2030)

• Bladder Cancer

• Kaposi Sarcoma

• Leukemia

• Lymphoma

• Breast Cancer

• Other

Doxorubicin Distribution Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals Pharmacies

• Retail Pharmacies

• Online Pharmacies

Doxorubicin Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Saudi Arabia

  • Kuwait

  • UAE

  • South Africa

List of Key Players in the Doxorubicin Market

• Pfizer Inc.

• Johnson & Johnson Services, Inc.

• Sun Pharmaceutical Industries Ltd

• Cipla.

• Cadila Pharmaceuticals.

• Novartis AG

• Dr. Reddy’s Laboratories Ltd.

• SRS Life Sciences

• MicroBiopharm Japan Co., Ltd.

• Baxter.